Clonal hematopoiesis in sickle cell disease

Clonal hematopoiesis in sickle cell disease

BACKGROUND. Curative gene therapies for sickle cell disease (SCD) are currently undergoing clinical evaluation. The occurrence of myeloid malignancies in these trials has prompted safety concerns. Individuals with SCD are predisposed to myeloid malignancies, but the underlying causes remain undefine...

Full description

Bibliographic Details
Main Authors: Abecasis, G.R (Author), Ashley-Koch, A. (Author), Bick, A.G (Author), Carneiro-Proietti, A.B (Author), Cato, L.D (Author), Custer, B. (Author), Dinardo, C.L (Author), Garrett, M.E (Author), Gladwin, M.T (Author), Kelly, S. (Author), Liggett, L.A (Author), Loureiro, P. (Author), Maximo, C. (Author), Natarajan, P. (Author), NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium (Author), Nouraie, S.M (Author), Reiner, A.P (Author), Sabino, E.C (Author), Sankaran, V.G (Author), Telen, M.J (Author), Weinstock, J.S (Author), Williams, D.A (Author), Zhang, Y. (Author)
Format: Article
Language:English
Published: American Society for Clinical Investigation 2022
Subjects:
adolescent
adult
aged
Anemia, Sickle Cell
Article
child
clinical article
clinical trial
clonal hematopoiesis
Clonal Hematopoiesis
cohort analysis
controlled study
disease severity
female
Female
genetics
genotype
hemoglobin F
human
Humans
hydroxyurea
male
Male
multicenter study
prevalence
sickle cell anemia
somatic mutation
treatment duration
whole genome sequencing
Whole Genome Sequencing
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items